"Breakthrough technology" and performing a "perfect total knee replacement" is how OMNIlife science, Inc. described its Active Spacer robotic tissue balancing device just cleared by the FDA.
In a September 6, 2017 announcement, the company said the new technology, in clinical use since March in Australia, "provides the surgeon with a quantitative tool to actively manage the soft tissue envelope with dynamic real-time feedback. When combined with the accuracy of alignment and bone cuts provided by the OMNIBotics system, the result is a completely customized procedure from both a skeletal perspective as well as a soft tissue perspective."
"This is a major milestone for both OMNI and for the orthopedic market," stated Vice President of Robotics Christian Joly. "We are now the only company in the world to provide a robotic technology to quantitatively drive the total knee replacement (TKR) surgical procedure with both alignment and ligament balancing."
OMNIlife science is privately held and located in Raynham, Massachusetts.